Amphastar Pharmaceuticals, Inc.
Cash Flow Statement
| Line Item | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $37.9M | $43.2M | $36.2M | $49.2M | $26.1M | $26.0M | $33.9M | $15.9M |
| Depreciation & Amortization | $13.1M | $9.7M | $9.7M | $9.6M | $3.1M | $3.4M | $3.4M | $3.4M |
| Depreciation | $7.0M | $6.8M | $6.6M | $6.4M | $5.9M | $6.3M | $6.2M | $6.2M |
| Amortization | $6.2M | $6.2M | $6.2M | $6.2M | $230.0K | $241.0K | $224.0K | $226.0K |
| Stock-Based Compensation | $5.8M | $7.4M | $4.6M | $4.6M | $4.9M | $6.1M | $4.3M | $4.3M |
| Net Cash from Operating Activities | $69.1M | $55.3M | $23.9M | $64.3M | $54.9M | $40.4M | $15.2M | $20.4M |
| Investing Activities | ||||||||
| Capital Expenditures | $6.0M | $8.8M | $9.4M | $10.2M | $9.1M | $9.5M | $6.3M | $5.6M |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-69.9M | $15.2M | $-103.0M | $-31.2M | $-508.6M | $-6.3M | $-229.0K | $-15.3M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | $0 | $50.0M | $128.0K | $8.0M | $18.1M | $14.5M |
| Net Cash from Financing Activities | $-10.7M | $-13.6M | $-47.1M | $86.6M | $428.1M | $-13.5M | $-16.2M | $-13.9M |
| Net Change in Cash | $-11.5M | $56.9M | $-126.5M | $119.8M | $-25.6M | $20.5M | $-1.1M | $-8.9M |
| Free Cash Flow | $63.1M | $46.5M | $14.4M | $54.1M | $45.9M | $30.9M | $8.9M | $14.8M |